PALLESCHI, MICHELA
PALLESCHI, MICHELA
Dottorandi
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer
2017 Gamucci T.; Mentuccia L.; Natoli C.; Sperduti I.; Cassano A.; Michelotti A.; Di Lauro L.; Sergi D.; Fabi A.; Sarobba M.G.; Marchetti P.; Barba M.; Magnolfi E.; Maugeri-Sacca M.; Rossi E.; Sini V.; Grassadonia A.; Pellegrini D.; Astone A.; Nistico C.; Angelini F.; Vaccaro A.; Pellegrino A.; De Angelis C.; Palleschi M.; Moscetti L.; Bertolini I.; Buglioni S.; Giordano A.; Pizzuti L.; Vici P.
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy
2024 Roberta Maltoni; Andrea Roncadori; William Balzi; Massimiliano Mazza; Fabio Nicolini; Michela Palleschi; Paola Ulivi; Sara Bravaccini
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?
2020 Maltoni R.; Palleschi M.; Altini M.; Massa I.; Balzi W.; Ravaioli S.; Tumedei M.M.; Rocca A.; Bravaccini S.
Are we ready to use TMB in breast cancer clinical practice?
2020 Ravaioli S.; Limarzi F.; Tumedei M.M.; Palleschi M.; Maltoni R.; Bravaccini S.
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter
2020 Bravaccini S.; Ravaioli S.; Tumedei M.M.; Rocca A.; Palleschi M.; Puccetti M.; Parrella P.; Altini M.; Maltoni R.
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
2021 Palleschi M.; Scarpi E.; Casadei C.
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report
2020 Palleschi M.; Maltoni R.; Barzotti E.; Melegari E.; Curcio A.; Cecconetto L.; Sarti S.; Manunta S.; Rocca A.
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer
2022 Gianni, Caterina; Palleschi, Michela; Merloni, Filippo; Di Menna, Giandomenico; Sirico, Marianna; Sarti, Samanta; Virga, Alessandra; Ulivi, Paola; Cecconetto, Lorenzo; Mariotti, Marita; De Giorgi, Ugo
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
2020 Maltoni R.; Palleschi M.; Ravaioli S.; Tumedei M.M.; Rocca A.; Melegari E.; Altini M.; Puccetti M.; Manunta S.; Bravaccini S.
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
2022 Gianni C.; Palleschi M.; Schepisi G.; Casadei C.; Bleve S.; Merloni F.; Sirico M.; Sarti S.; Cecconetto L.; Di Menna G.; Schettini F.; De Giorgi U.
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab
2022 Palleschi M.; Prochowski Iamurri A.; Scarpi E.; Mariotti M.; Maltoni R.; Mannozzi F.; Barone D.; Paganelli G.; Casi M.; Giampalma E.; De Giorgi U.; Rocca A.
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis
2022 Rossi T.; Angeli D.; Tebaldi M.; Fici P.; Rossi E.; Rocca A.; Palleschi M.; Maltoni R.; Martinelli G.; Fabbri F.; Gallerani G.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
2021 Del Re M.; Omarini C.; Diodati L.; Palleschi M.; Meattini I.; Crucitta S.; Lorenzini G.; Isca C.; Fontana A.; Livi L.; Piacentini F.; Fogli S.; De Giorgi U.; Danesi R.
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET
In corso di stampa A. Gennari, E. Brain, A. De Censi, O. Nanni, R. Wuerstlein, A. Frassoldati, J. Cortes, V. Rossi, M. Palleschi, J.L. Alberini, F. Matteucci, A. Piccardo, G. Sacchetti, H. Ilhan, F. D’Avanzo, B. Ruffilli, S. Nardin, M. Monti, M. Puntoni, V. Fontana, L. Boni, N. Harbeck,
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
2023 Munzone E, Regan MM, Cinieri S, Montagna E, Orlando L, Shi R, Campadelli E, Gianni L, Palleschi M, Petrelli F, Bengala C, Generali D, Collovà E, Puglisi F, Cretella E, Zamagni C, Chini C, Ruepp B, Loi S, Colleoni M; International Breast Cancer Study Group (IBCSG).
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial
2021 Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F;
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor
2021 Palleschi M.; Iaia M.L.; Casadei C.
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?
2020 Palleschi M.; Maltoni R.; Sarti S.; Melegari E.; Bravaccini S.; Rocca A.
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 Vernieri C.; Nichetti F.; Lalli L.; Moscetti L.; Giorgi C.A.; Griguolo G.; Marra A.; Randon G.; Rea C.G.; Ligorio F.; Scagnoli S.; De Angelis C.; Molinelli C.; Fabbri A.; Ferraro E.; Trapani D.; Milani A.; Agostinetto E.; Bernocchi O.; Catania G.; Vantaggiato A.; Palleschi M.; Moretti A.; Basile D.; Cinausero M.; Ajazi A.; Castagnoli L.; Vullo S.L.; Gerratana L.; Puglisi F.; La Verde N.; Arpino G.; Rocca A.; Ciccarese M.; Pedersini R.; Fabi A.; Generali D.; Losurdo A.; Montemurro F.; Curigliano G.; Del Mastro L.; Michelotti A.; Cortesi E.; Guarneri V.; Pruneri G.; Mariani L.; De Braud F.
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience
2020 Palleschi M.; Maltoni R.; Ravaioli S.; Vagheggini A.; Mannozzi F.; Fanini F.; Pirini F.; Tumedei M.M.; Barzotti E.; Cecconetto L.; Sarti S.; Manunta S.; Possanzini P.; Fedeli A.; Curcio A.; Altini M.; de Giorgi U.; Rocca A.; Bravaccini S.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer | Gamucci T.; Mentuccia L.; Natoli C.; Sperduti I.; Cassano A.; Michelotti A.; Di Lauro L.; Sergi D....; Fabi A.; Sarobba M.G.; Marchetti P.; Barba M.; Magnolfi E.; Maugeri-Sacca M.; Rossi E.; Sini V.; Grassadonia A.; Pellegrini D.; Astone A.; Nistico C.; Angelini F.; Vaccaro A.; Pellegrino A.; De Angelis C.; Palleschi M.; Moscetti L.; Bertolini I.; Buglioni S.; Giordano A.; Pizzuti L.; Vici P. | 2017-01-01 | JOURNAL OF CELLULAR PHYSIOLOGY | - | 1.01 Articolo in rivista | Journal Cellular Physiology - 2016 - Gamucci - A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and.pdf |
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy | Roberta Maltoni; Andrea Roncadori; William Balzi; Massimiliano Mazza; Fabio Nicolini; Michela Pal...leschi; Paola Ulivi; Sara Bravaccini | 2024-01-01 | BIOMEDICINES | - | 1.01 Articolo in rivista | - |
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? | Maltoni R.; Palleschi M.; Altini M.; Massa I.; Balzi W.; Ravaioli S.; Tumedei M.M.; Rocca A.; Bra...vaccini S. | 2020-01-01 | CLINICAL BREAST CANCER | - | 1.04 Replica / breve intervento (e simili) | - |
Are we ready to use TMB in breast cancer clinical practice? | Ravaioli S.; Limarzi F.; Tumedei M.M.; Palleschi M.; Maltoni R.; Bravaccini S. | 2020-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.04 Replica / breve intervento (e simili) | - |
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter | Bravaccini S.; Ravaioli S.; Tumedei M.M.; Rocca A.; Palleschi M.; Puccetti M.; Parrella P.; Altin...i M.; Maltoni R. | 2020-01-01 | CLINICAL CANCER RESEARCH | - | 1.04 Replica / breve intervento (e simili) | - |
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? | Palleschi M.; Scarpi E.; Casadei C. | 2021-01-01 | BREAST CANCER RESEARCH AND TREATMENT | - | 1.01 Articolo in rivista | - |
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report | Palleschi M.; Maltoni R.; Barzotti E.; Melegari E.; Curcio A.; Cecconetto L.; Sarti S.; Manunta S....; Rocca A. | 2020-01-01 | WORLD JOURNAL OF CLINICAL CASES | - | 1.04 Replica / breve intervento (e simili) | - |
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer | Gianni, Caterina; Palleschi, Michela; Merloni, Filippo; Di Menna, Giandomenico; Sirico, Marianna;... Sarti, Samanta; Virga, Alessandra; Ulivi, Paola; Cecconetto, Lorenzo; Mariotti, Marita; De Giorgi, Ugo | 2022-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | graphic.pdf; ijms-23-14197.pdf |
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer | Maltoni R.; Palleschi M.; Ravaioli S.; Tumedei M.M.; Rocca A.; Melegari E.; Altini M.; Puccetti M....; Manunta S.; Bravaccini S. | 2020-01-01 | CELL TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment | Gianni C.; Palleschi M.; Schepisi G.; Casadei C.; Bleve S.; Merloni F.; Sirico M.; Sarti S.; Cecc...onetto L.; Di Menna G.; Schettini F.; De Giorgi U. | 2022-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab | Palleschi M.; Prochowski Iamurri A.; Scarpi E.; Mariotti M.; Maltoni R.; Mannozzi F.; Barone D.; ...Paganelli G.; Casi M.; Giampalma E.; De Giorgi U.; Rocca A. | 2022-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | - |
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis | Rossi T.; Angeli D.; Tebaldi M.; Fici P.; Rossi E.; Rocca A.; Palleschi M.; Maltoni R.; Martinell...i G.; Fabbri F.; Gallerani G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-03925-v2.pdf; cancers-14-03925-s001.zip |
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients | Del Re M.; Omarini C.; Diodati L.; Palleschi M.; Meattini I.; Crucitta S.; Lorenzini G.; Isca C.;... Fontana A.; Livi L.; Piacentini F.; Fogli S.; De Giorgi U.; Danesi R. | 2021-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | - |
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET | A. Gennari, E. Brain, A. De Censi, O. Nanni, R. Wuerstlein, A. Frassoldati, J. Cortes, V. Rossi, ...M. Palleschi, J.L. Alberini, F. Matteucci, A. Piccardo, G. Sacchetti, H. Ilhan, F. D’Avanzo, B. Ruffilli, S. Nardin, M. Monti, M. Puntoni, V. Fontana, L. Boni, N. Harbeck, | 9999-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. | Munzone E, Regan MM, Cinieri S, Montagna E, Orlando L, Shi R, Campadelli E, Gianni L, Palleschi M..., Petrelli F, Bengala C, Generali D, Collovà E, Puglisi F, Cretella E, Zamagni C, Chini C, Ruepp B, Loi S, Colleoni M; International Breast Cancer Study Group (IBCSG). | 2023-01-01 | JAMA ONCOLOGY | - | 1.01 Articolo in rivista | - |
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial | Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, ...Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F; | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor | Palleschi M.; Iaia M.L.; Casadei C. | 2021-01-01 | BREAST CANCER RESEARCH AND TREATMENT | - | 1.04 Replica / breve intervento (e simili) | - |
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? | Palleschi M.; Maltoni R.; Sarti S.; Melegari E.; Bravaccini S.; Rocca A. | 2020-01-01 | THE BREAST JOURNAL | - | 1.04 Replica / breve intervento (e simili) | - |
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) | Vernieri C.; Nichetti F.; Lalli L.; Moscetti L.; Giorgi C.A.; Griguolo G.; Marra A.; Randon G.; R...ea C.G.; Ligorio F.; Scagnoli S.; De Angelis C.; Molinelli C.; Fabbri A.; Ferraro E.; Trapani D.; Milani A.; Agostinetto E.; Bernocchi O.; Catania G.; Vantaggiato A.; Palleschi M.; Moretti A.; Basile D.; Cinausero M.; Ajazi A.; Castagnoli L.; Vullo S.L.; Gerratana L.; Puglisi F.; La Verde N.; Arpino G.; Rocca A.; Ciccarese M.; Pedersini R.; Fabi A.; Generali D.; Losurdo A.; Montemurro F.; Curigliano G.; Del Mastro L.; Michelotti A.; Cortesi E.; Guarneri V.; Pruneri G.; Mariani L.; De Braud F. | 2021-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience | Palleschi M.; Maltoni R.; Ravaioli S.; Vagheggini A.; Mannozzi F.; Fanini F.; Pirini F.; Tumedei ...M.M.; Barzotti E.; Cecconetto L.; Sarti S.; Manunta S.; Possanzini P.; Fedeli A.; Curcio A.; Altini M.; de Giorgi U.; Rocca A.; Bravaccini S. | 2020-01-01 | DIAGNOSTICS | - | 1.01 Articolo in rivista | Ki67 and PR in Patients Treated with CDK4 6.pdf |